Global Cytomegalovirus Market, By Diagnosis (Serologic Test, Polymerase Chain Reaction (PCR) Test, Others), Diseases (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, Others), Drug (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir, Others), Route of Administration (Oral, Parenteral, Others), Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, Other), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The cytomegalovirus (CMV) is a widespread and usually harmless virus. If you have it while pregnant, it can pose issues in your baby (congenital CMV). Congenital CMV infection affects around one out of every 200 babies, according to the Centers for Disease Control and Prevention. CMV infection in the neonate results in a reduced interferon response compared to infection in adults. During pregnancy, CMV infection and the risk of reactivation of cytomegalovirus infection have been described. Congenital CMV infection can also result from these.
Data Bridge Market Research analyses that the cytomegalovirus market was valued at USD 535.70 million in 2021 and is expected to reach USD 886.57 million by 2029, registering a CAGR of 6.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Serologic Test, Polymerase Chain Reaction (PCR) Test, Others), Diseases (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, Others), Drug (Cidofovir, Foscarnet, Valganciclovir, Ganciclovir, Others), Route of Administration (Oral, Parenteral, Others), Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, Other), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Cipla Inc. (U.S.), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Endo International plc (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BD (U.S.), Abbott (US), Astellas Pharma Inc. (Japan), Merck & Co., Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Cytomegalovirus infection is a common herpesvirus infection that can cause a variety of symptoms, ranging from no symptoms to fever and exhaustion to severe symptoms affecting the eyes, brain, and other internal organs. CMV is a contagious disease that can be spread through blood, sperm, saliva, urine, and breast milk. The most prevalent method of treatment is antiviral medicine. They can slow the virus's reproduction but not inhibit it. Ganciclovir, foscarnet, valganciclovir, cidofovir, and other antiviral medications are commercially available to treat cytomegalovirus.
Cytomegalovirus Market Dynamics
Drivers
- Rise in the prevalence of cytomegalovirus infection
The surging prevalence of cytomegalovirus infection is a major factor driving the market's growth rate during the forecast period of 2022-2029. In the United States, one in every 150 infants is born with congenital cytomegalovirus (CMV) infection, according to the Centers for Disease Control and Prevention (CDC). Only one out of every five infants infected with CMV develops long-term health issues. The CMV infection treatment and diagnosis market will rise due to rising infection rates and desire for improved treatment options.
- Growing prevalence of viral infections
The need for cytomegalovirus medicines is expected to rise as the prevalence of viral infections among AIDS patient’s increases due to weakening immune systems. According to the CDC, around 36.7 million people were living with human immunodeficiency virus (HIV) infection in 2017. The widespread availability of antiviral medications to treat this condition is anticipated to stimulate the demand for effective treatment options. This will influence the market’s growth rate.
Furthermore, sedentary lifestyle of people and rising number of initiatives by government to spread awareness will result in the expansion of cytomegalovirus market. Along with this, rising healthcare expenditure and expiry of patents which leads to the availability of generic drugs will enhance the growth rate of the market. Also, increasing number of organ transplantation globally is estimated to enhance the market’s growth rate.
Opportunities
- Increase in the number of research and development activities
The rising number of research and development activities for new indications and patent expiry of biologics is estimated to create new opportunities for the cytomegalovirus market growth in coming years. Various projects focused on R&D efforts linked to cytomegalovirus (CMV) infection are being launched by major institutes. For instance, the University of Washington's Program for Advanced Cell Therapy (PACT) launched a first-in-the-US cell-therapy trial for kidney transplant patients in August 2019 that will use virus-specific white blood cells in the treatment of patients with severe cytomegalovirus (CMV) infection after kidney transplantation.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cytomegalovirus market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the cytomegalovirus market. Additionally, lack of awareness among people and side effects linked with medications will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This cytomegalovirus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cytomegalovirus market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to the Centers for Disease Control and Prevention (CDC), more than half of all persons in the United States have contracted the virus by the age of 40. It affects both men and women equally, regardless of age or ethnicity.
Cytomegalovirus market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In November 2021, Takeda Pharmaceutical Company Limited had announced the U.S. Food and Drug Administration (FDA) approval for LIVTENCITY (maribavir) for the treatment of adults and pediatric patients along with post-transplant cytomegalovirus (CMV) infection that is refractory to treatment with ganciclovir, cidofovir, valganciclovir or foscarnet. LIVTENCITY is a type of new molecular entity which targets CMV at pUL97 and further causes inhibition of viral DNA replication, nuclear egress and encapsidation.
Global Cytomegalovirus Market Scope
The cytomegalovirus market is segmented on the basis of diagnosis, diseases, drugs, application, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Serologic Test
- Polymerase Chain Reaction (PCR) Test
- Others
Diseases
Drug
- Cidofovir
- Foscarnet
- Valganciclovir
- Ganciclovir
- Others
Application
- Stem Cell Transplantation
- Organ Transplantation
- Congenital CMV Infection
- Other
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Cytomegalovirus Market Regional Analysis/Insights
The cytomegalovirus market is analysed and market size insights and trends are provided by country, diseases, diagnosis, drugs, application, route of administration, end-users and distribution channel as referenced above.
The countries covered in the cytomegalovirus market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the cytomegalovirus market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, introduction of newer drugs will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to large number of generic manufacturer in this region. Also, development of healthcare infrastructure and rising number of population will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cytomegalovirus Market Share Analysis
The cytomegalovirus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cytomegalovirus market.
Some of the major players operating in the cytomegalovirus market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Zydus Cadila (India)
- Lupin (India)
- Cipla Inc. (U.S.)
- Aurobindo Pharma (India)
- Glenmark Pharmaceuticals Limited (India)
- Endo International plc (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BD (U.S.)
- Abbott (US)
- Astellas Pharma Inc. (Japan)
- Merck & Co., Inc. (U.S.)
SKU-